An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Senate committee members heard arguments on a bill that would place a 10-year pause on administering mRNA vaccines in Idaho ...
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...
The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback